CJC-1295 Protocol: Complete Cycling & Dosing Guide

Overview

CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog engineered with Drug Affinity Complex (DAC) technology to extend its circulating half-life from minutes to 6–8 days. This extended duration allows once-weekly dosing and sustained pituitary stimulation, making it a practical tool for those seeking to enhance endogenous growth hormone (GH) and insulin-like growth factor-1 (IGF-1) production.

Unlike exogenous GH, CJC-1295 works by signaling your own anterior pituitary to manufacture and release GH in a pulsatile pattern. This is achieved through activation of the GHRH receptor (GHRHR) on somatotroph cells. The DAC modification covalently binds CJC-1295 to serum albumin via a maleimide-lysine linkage, extending its bioavailability and allowing receptor stimulation to persist across multiple days.

What to Expect at a Glance

• Half-life: 5.8–8.1 days (one injection per week)
• Typical dosing: 1,000–2,000 mcg (1–2 mg) weekly
• Route: Subcutaneous injection
• Onset: GH elevation begins within hours; IGF-1 peaks around day 4–7
• Cost: $40–$120 per month
• Most common side effect: Mild injection site irritation
• FDA status: Not approved for human use; research purposes only

Standard Protocol

Foundational Dosing Strategy

The standard CJC-1295 protocol follows a simple once-weekly injection schedule. Most users begin with 1,000 mcg (1 mg) per week and titrate upward based on tolerance and response.

Beginner Protocol:

• Dose: 1,000 mcg (1 mg) per week
• Frequency: Once weekly, same day and time
• Duration: 12–16 weeks
• Rest period: 4 weeks off before resuming

Intermediate Protocol:

• Dose: 1,500 mcg (1.5 mg) per week
• Frequency: Once weekly
• Duration: 16–20 weeks
• Rest period: 4–6 weeks off

Advanced Protocol:

• Dose: 2,000 mcg (2 mg) per week (upper range)
• Frequency: Once weekly
• Duration: 16–24 weeks
• Rest period: 6–8 weeks off

Dose Escalation

If tolerating 1,000 mcg without side effects after 3–4 weeks, increase in 250–500 mcg increments every 2–3 weeks until reaching your target dose. This gradual approach minimizes injection site reactions and allows you to identify your optimal dose.

Example escalation:

• Week 1–3: 1,000 mcg weekly
• Week 4–6: 1,250 mcg weekly
• Week 7–9: 1,500 mcg weekly
• Week 10+: Maintain 1,500–2,000 mcg weekly

Goal-Specific Protocols

Evidence for CJC-1295's efficacy varies significantly by outcome. Below are realistic protocols aligned with what the literature supports:

For Hormonal Optimization (Strongest Evidence)

Duration: 16–20 weeks

CJC-1295 reliably elevates GH and IGF-1 in controlled settings. A single injection produces 2–10 fold increases in mean plasma GH sustained for 6+ days and 1.5–3 fold increases in IGF-1 for 9–11 days. With repeated dosing, IGF-1 remains elevated for up to 28 days.

• Dose: 1,500–2,000 mcg weekly
• Testing schedule: Baseline (before start), week 8, and week 16
  • Check: serum GH (fasting, 2–4 hours post-injection ideal), IGF-1, fasting glucose, lipid panel
• Expected outcome: 2–3 fold elevation in baseline IGF-1; sustained GH secretion

For Muscle Development (Moderate Theoretical Support)

Duration: 12–20 weeks

No human trials directly measure muscle gain from CJC-1295 alone, though it reliably increases GH and IGF-1. Most experienced users combine it with a GHRP (such as Ipamorelin) to amplify pulsatile GH release.

• Dose: 1,500–2,000 mcg CJC-1295 weekly
• Co-administration: Consider 50–100 mcg Ipamorelin 1–2 times daily (see stacking section)
• Nutrition: Caloric surplus with 0.8–1 g protein per lb bodyweight
• Training: Progressive resistance training, 4–5 days weekly
• Expected outcome: Theoretical increase in lean mass accrual; synergy with training and nutrition

For Body Composition (Limited Evidence)

Duration: 12–16 weeks

Available evidence consists of forum discussions and one animal study in knockout mice—not robust data. However, elevated GH and IGF-1 promote lipolytic effects (fat mobilization) while sparing lean tissue.

• Dose: 1,000–1,500 mcg weekly
• Caloric approach: Modest deficit (300–500 cal below maintenance)
• Expected outcome: Theoretical fat loss acceleration; no proven clinical efficacy in humans

For Recovery (Theoretical Only)

Duration: 8–12 weeks post-injury

CJC-1295 is proposed theoretically to activate IGF-1 signaling relevant to tissue repair, but no clinical trial data confirms efficacy for injury recovery.

• Dose: 1,000–1,500 mcg weekly
• Duration: Initiate within days of acute injury; continue 8–12 weeks
• Adjuncts: Physical therapy, adequate sleep, protein intake (1 g per lb bodyweight)
• Expected outcome: Theoretical acceleration of tissue remodeling; not clinically proven

How to Administer: Step-by-Step

Preparation & Reconstitution

CJC-1295 is supplied as a lyophilized powder and must be reconstituted before injection.

1. Gather supplies: 1 vial CJC-1295 powder, bacteriostatic water (BAC water), sterile syringe (1 mL insulin syringe), sterile needle (29–31 gauge for injection)
2. Aseptic technique: Work in a clean, well-lit area. Wash hands thoroughly.
3. Draw bacteriostatic water: Using a fresh syringe and needle, draw the appropriate volume of BAC water. A common ratio is 1 mL BAC water per 1 mg CJC-1295 powder, yielding 1 mg/mL concentration. Adjust based on your desired injection volume (typically 10–20 mcL per injection is easier to measure accurately than 100+ mcL).
4. Inject into vial: Insert the needle through the rubber stopper of the CJC-1295 vial and slowly inject BAC water against the inner vial wall (not directly onto the powder).
5. Let stand: Allow the powder to dissolve gently for 2–3 minutes without shaking. Gentle rolling between your palms accelerates dissolution.
6. Verify clarity: The final solution should be clear and colorless. Do not use if cloudy or particulate matter is visible.
7. Label and store: Mark the vial with the reconstitution date and concentration. Store in a refrigerator at 2–8°C.
8. Stability: Once reconstituted, CJC-1295 remains stable for up to 3 weeks when refrigerated.

Injection Technique

1. Choose injection site: Subcutaneous injection into the abdomen (1–2 inches from navel), outer thigh, or upper arm. Rotate sites weekly to minimize irritation and lipohypertrophy.
2. Sanitize: Swab the injection site with an alcohol prep pad and allow to air dry for 10 seconds.
3. Draw dose: Using a fresh insulin syringe, draw your weekly dose (e.g., 1.5 mL of a 1 mg/mL solution = 1,500 mcg).
4. Inject: Pinch the subcutaneous tissue between your thumb and forefinger, insert the needle at a 45° angle, and slowly inject the solution.
5. Withdraw and apply pressure: Remove the needle and apply gentle pressure with a sterile cotton ball for 10–15 seconds.
6. Monitor for bleeding: If bleeding occurs, apply mild pressure until it stops.

Cycle Example: Week-by-Week Schedule

16-Week Standard Cycle

20-Week Intermediate Cycle with Escalation to 2,000 mcg

What to Expect: Timeline of Effects

Days 1–3

• Possible injection site warmth, mild redness, or swelling (most common side effect)
• Possible flushing and sensation of skin warmth 30–60 minutes post-injection
• Increase in appetite within 12–24 hours
• Sleep may deepen slightly

Days 4–7

• GH elevation peaks; some users report transient fatigue or lethargy as hormone levels normalize
• Possible increase in water retention, particularly in hands and feet
• Appetite remains elevated
• IGF-1 begins to rise measurably

Week 2–3

• Injection site irritation typically resolves if rotating sites
• Fatigue, if present, diminishes
• Appetite stabilization
• Subtle improvements in sleep quality and recovery (subjective)

Week 4–8

• Water retention may persist but often stabilizes
• Cumulative IGF-1 elevation becomes significant (measurable by lab)
• Some users report subjective improvements in mood, energy, and recovery
• Injection site reactions generally minimal with proper rotation

Week 8–16

• Sustained GH and IGF-1 elevation; most effects plateau
• Continued appetite stimulation
• Possible subtle increases in muscle fullness (if combined with resistance training and adequate nutrition)
• Possible subtle improvements in skin hydration and hair quality (anecdotal; not clinically proven)

Common Protocol Mistakes

Injecting Too Frequently

Many users mistakenly inject CJC-1295 multiple times per week. Due to its 6–8 day half-life, this is unnecessary and increases side effects. Stick to once weekly.

Inadequate Injection Site Rotation

Repeatedly injecting into the same location causes lipohypertrophy (fat thickening) and chronic irritation. Rotate between abdomen, thighs, and upper arms. Space injections at least 1 inch apart.

Reconstituting with Non-Bacteriostatic Water

Using regular sterile water or saline accelerates bacterial growth and peptide degradation. Always use bacteriostatic water (BAC water).

Skipping Rest Periods

Continuous use without breaks may suppress endogenous GHRH signaling. Plan 4–8 week rest periods between cycles to allow pituitary recovery.

Not Tracking Injection Dates

Missing injections or doubling up "to catch up" disrupts the steady-state hormone elevation. Use a calendar or reminder app to maintain consistent weekly timing.

Ignoring Early Side Effects

Severe injection site reactions, persistent edema, or blood glucose dysregulation may indicate the need for dose reduction or cycle termination. Do not ignore warning signs.

How to Stack with Other Compounds

CJC-1295 + Ipamorelin (Most Common Stack)

Ipamorelin is a ghrelin receptor agonist (GHRP) that synergistically amplifies GH secretion when combined with CJC-1295. This stack is popular because it mimics the body's natural GH pulse more closely.

Protocol:

• CJC-1295: 1,500–2,000 mcg once weekly (same as monotherapy)
• Ipamorelin: 50–100 mcg, 1–3 times daily via subcutaneous injection
  • Example: Morning injection (fasted or with minimal carbs), post-workout, and/or before bed
• Duration: 12–20 weeks
• Rest: 4–6 weeks between cycles

Rationale: CJC-1295 provides sustained basal GH stimulation; Ipamorelin creates acute pulsatile spikes. Together, they produce more physiological GH elevation than either alone.

CJC-1295 + Testosterone (Advanced Users)

This stack amplifies muscle-building effects, though testosterone introduces greater suppression of endogenous hormone production.

Protocol (example):

• CJC-1295: 1,500–2,000 mcg weekly
• Testosterone Enanthate or Cypionate: 300–500 mg weekly (or adjusted based on experience)
• Duration: 12–16 weeks on; 8–12 weeks off + PCT (post-cycle therapy)
• PCT: Consider a SERM (e.g., tamoxifen or clomiphene) to restore endogenous testosterone

Caution: This stack significantly increases cardiovascular strain, insulin resistance risk, and hepatic lipid changes. Monitor lipid panels and blood pressure closely.

CJC-1295 + Minimal Adjuncts (Conservative Approach)

For those prioritizing hormonal optimization without stacking:

• CJC-1295: 1,000–1,500 mcg weekly
• Sleep optimization: Consistent 7–9 hours nightly
• Nutrition: Caloric maintenance or modest surplus; adequate protein
• Training: Progressive resistance training 4–5 days weekly

This approach minimizes side effects while relying on CJC-1295's GH-stimulating properties and baseline lifestyle factors.

Protocol Quick Reference Table

Signs It's Working & When to Adjust

Positive Indicators

• Lab confirmation: IGF-1 elevation of 1.5–3× baseline by week 8–12
• Improved sleep: Deeper, more restorative sleep within 2–4 weeks
• Appetite increase: Noticeable increase in hunger, especially beneficial if in caloric surplus
• Recovery: Faster recovery from training;